Cover Image
市場調查報告書

異動症 : 開發平台分析

Dyskinesia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192566
出版日期 內容資訊 英文 170 Pages
訂單完成後即時交付
價格
Back to Top
異動症 : 開發平台分析 Dyskinesia - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 170 Pages
簡介

所謂異動症(Dyskinesia)是指肌肉的不自主運動,或是難以隨意運重肌肉的狀態。主要的症狀有顏面扭曲、手指不自主動作、下巴搖動、重覆嚼動、吐舌等。有可能靠健康的生活型態或藥物療法來抑制症狀。

本報告提供全球各國治療異動症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

異動症概要

治療藥的開發

  • 異動症開發中產品:概要
  • 異動症開發中產品:比較分析

各企業開發中的異動症治療藥

大學/研究機關研究中的治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

異動症治療藥:開發中的產品的一覽(各企業)

異動症治療藥:開發中的產品的一覽(大學/研究機關別)

異動症開發治療藥的企業

  • Adamas Pharmaceuticals, Inc.
  • Addex Therapeutics Ltd
  • Advicenne Pharma
  • Amarantus Bioscience Holdings, Inc.
  • Astraea Therapeutics, LLC
  • BioMarin Pharmaceutical Inc.
  • Catalyst Biosciences, Inc.
  • Catalyst Pharmaceutical Partners, Inc.
  • Cerecor Inc.
  • Contera Pharma ApS
  • EpiVax, Inc.
  • Heptares Therapeutics Limited
  • Hua Medicine Ltd.
  • Integrative Research Laboratories Sweden AB
  • Ipsen S.A.
  • Medy-Tox Inc.
  • Merz Pharmaceuticals GmbH
  • MitoDys Therapeutics Limited
  • Neurim Pharmaceuticals Ltd
  • Neurocrine Biosciences, Inc.
  • Neurolixis Inc.
  • Osmotica Pharmaceutical Corp.
  • 大塚集團
  • Revance Therapeutics, Inc.
  • Santhera Pharmaceuticals Holding AG
  • SciFluor Life Sciences, LLC
  • Synchroneuron Inc.
  • Teva Pharmaceutical Industries Limited

異動症:治療藥的評估

    單劑治療藥的情況

    並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • dextromethorphan hydrobromide+quinidine sulfate
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • A2M-13677
  • abobotulinumtoxin A
  • abobotulinumtoxin A next generation
  • acamprosate calcium SR
  • amantadine hydrochloride ER
  • amantadine hydrochloride ER
  • AT-127
  • AT-326
  • AT-403
  • befiradoru
  • CERC-406
  • CPP-115
  • dipraglurant ER
  • dipraglurant IR
  • 異動症治療藥
  • 遲發性運動障礙治療藥
  • dutetrabenazine ER
  • erutopurajin
  • fipamezoru
  • HTL-14242
  • IRL-790
  • JM-010
  • MLR-1019
  • MRZ-8676
  • Neu-120
  • Neu-240
  • onabotulinumtoxin A
  • onabotulinumtoxin A
  • PEUN-3
  • RG-2833
  • RT-002 1
  • SK-609 1
  • 異動症小分子
  • 異動症·運動過多障礙抑制劑
  • Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia
  • 中樞神經系統疾病代謝型麩胺酸受體5(mGluR5)中和用小分子
  • 異動症代謝型麩胺酸受體5(mGluR5)中和用小分子
  • TC-8831
  • tetra山毛櫸琴酒
  • valbenazine
  • VU-0431316

異動症治療藥:開發中產品的最新趨勢

異動症治療藥:開發暫停的產品

異動症治療藥:開發中止的產品

異動症相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8451IDB

Summary

Global Markets Direct's, 'Dyskinesia - Pipeline Review, H2 2016', provides an overview of the Dyskinesia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Dyskinesia
  • The report reviews pipeline therapeutics for Dyskinesia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Dyskinesia therapeutics and enlists all their major and minor projects
  • The report assesses Dyskinesia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Dyskinesia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Dyskinesia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Dyskinesia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Dyskinesia Overview
  • Therapeutics Development
    • Pipeline Products for Dyskinesia - Overview
    • Pipeline Products for Dyskinesia - Comparative Analysis
  • Dyskinesia - Therapeutics under Development by Companies
  • Dyskinesia - Therapeutics under Investigation by Universities/Institutes
  • Dyskinesia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Dyskinesia - Products under Development by Companies
  • Dyskinesia - Products under Investigation by Universities/Institutes
  • Dyskinesia - Companies Involved in Therapeutics Development
    • Adamas Pharmaceuticals, Inc.
    • Addex Therapeutics Ltd
    • Advicenne
    • Astraea Therapeutics, LLC
    • Bionomics Limited
    • Catalyst Biosciences, Inc.
    • Catalyst Pharmaceuticals, Inc.
    • Clevexel Pharma SAS
    • Contera Pharma ApS
    • EpiVax, Inc.
    • Heptares Therapeutics Limited
    • Hua Medicine (Shanghai) Ltd.
    • Integrative Research Laboratories Sweden AB
    • Ipsen S.A.
    • Merz Pharma GmbH & Co. KgaA
    • MitoDys Therapeutics Limited
    • Neurim Pharmaceuticals Ltd
    • Neurocrine Biosciences, Inc.
    • Neurolixis Inc.
    • Osmotica Pharmaceutical Corp.
    • Otsuka Holdings Co., Ltd.
    • Phenomenome Discoveries, Inc.
    • Revance Therapeutics, Inc.
    • Sage Therapeutics, Inc.
    • SciFluor Life Sciences, LLC
    • SOM Innovation Biotech SL
    • Synchroneuron Inc.
    • Teva Pharmaceutical Industries Ltd.
  • Dyskinesia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (dextromethorphan + quinidine sulfate) - Drug Profile
    • A2M-13677 - Drug Profile
    • abobotulinumtoxin A - Drug Profile
    • acamprosate calcium SR - Drug Profile
    • amantadine hydrochloride ER - Drug Profile
    • amantadine hydrochloride ER - Drug Profile
    • AT-127 - Drug Profile
    • AT-326 - Drug Profile
    • AT-403 - Drug Profile
    • befiradol - Drug Profile
    • CPP-115 - Drug Profile
    • CVXL-0107 - Drug Profile
    • deutetrabenazine ER - Drug Profile
    • dipraglurant ER - Drug Profile
    • dipraglurant IR - Drug Profile
    • Drug for Dyskinesia - Drug Profile
    • HTL-14242 - Drug Profile
    • incobotulinumtoxin A - Drug Profile
    • IRL-790 - Drug Profile
    • JM-010 - Drug Profile
    • MLR-1019 - Drug Profile
    • NBI-640756 - Drug Profile
    • Neu-120 - Drug Profile
    • Neu-240 - Drug Profile
    • onabotulinumtoxinA - Drug Profile
    • PEUN-3 - Drug Profile
    • PPI-1011 - Drug Profile
    • remeglurant - Drug Profile
    • RT-002 - Drug Profile
    • SAGE-217 - Drug Profile
    • sepranolone - Drug Profile
    • SK-609 - Drug Profile
    • Small Molecule for Dyskinesia - Drug Profile
    • Small Molecule for Dyskinesia and Hyperkinesia - Drug Profile
    • Small Molecules for Neurodegenerative Disease - Drug Profile
    • Small Molecules for Tardive Dyskinesia - Drug Profile
    • Small Molecules to Antagonize GPCR for Central Nervous System Diseases - Drug Profile
    • Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia - Drug Profile
    • Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile
    • Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile
    • Small Molecules to Target Ion Channels for CNS Disorders - Drug Profile
    • SOM-3355 - Drug Profile
    • TC-8831 - Drug Profile
    • tetrabenazine - Drug Profile
    • valbenazine tosylate - Drug Profile
  • Dyskinesia - Dormant Projects
  • Dyskinesia - Discontinued Products
  • Dyskinesia - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Dyskinesia, H2 2016
  • Number of Products under Development for Dyskinesia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Dyskinesia - Pipeline by Adamas Pharmaceuticals, Inc., H2 2016
  • Dyskinesia - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Dyskinesia - Pipeline by Advicenne, H2 2016
  • Dyskinesia - Pipeline by Astraea Therapeutics, LLC, H2 2016
  • Dyskinesia - Pipeline by Bionomics Limited, H2 2016
  • Dyskinesia - Pipeline by Catalyst Biosciences, Inc., H2 2016
  • Dyskinesia - Pipeline by Catalyst Pharmaceuticals, Inc., H2 2016
  • Dyskinesia - Pipeline by Clevexel Pharma SAS, H2 2016
  • Dyskinesia - Pipeline by Contera Pharma ApS, H2 2016
  • Dyskinesia - Pipeline by EpiVax, Inc., H2 2016
  • Dyskinesia - Pipeline by Heptares Therapeutics Limited, H2 2016
  • Dyskinesia - Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016
  • Dyskinesia - Pipeline by Integrative Research Laboratories Sweden AB, H2 2016
  • Dyskinesia - Pipeline by Ipsen S.A., H2 2016
  • Dyskinesia - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016
  • Dyskinesia - Pipeline by MitoDys Therapeutics Limited, H2 2016
  • Dyskinesia - Pipeline by Neurim Pharmaceuticals Ltd, H2 2016
  • Dyskinesia - Pipeline by Neurocrine Biosciences, Inc., H2 2016
  • Dyskinesia - Pipeline by Neurolixis Inc., H2 2016
  • Dyskinesia - Pipeline by Osmotica Pharmaceutical Corp., H2 2016
  • Dyskinesia - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Dyskinesia - Pipeline by Phenomenome Discoveries, Inc., H2 2016
  • Dyskinesia - Pipeline by Revance Therapeutics, Inc., H2 2016
  • Dyskinesia - Pipeline by Sage Therapeutics, Inc., H2 2016
  • Dyskinesia - Pipeline by SciFluor Life Sciences, LLC, H2 2016
  • Dyskinesia - Pipeline by SOM Innovation Biotech SL, H2 2016
  • Dyskinesia - Pipeline by Synchroneuron Inc., H2 2016
  • Dyskinesia - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Dyskinesia - Dormant Projects, H2 2016
  • Dyskinesia - Dormant Projects (Contd..1), H2 2016
  • Dyskinesia - Dormant Projects (Contd..2), H2 2016
  • Dyskinesia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Dyskinesia, H2 2016
  • Number of Products under Development for Dyskinesia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top